Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14826052 | 0.80 | DYRK1A (0.85) | DYRK1ACYP1A2METAP2TGFBR1KEAP1 | |
| SCHEMBL23162289 | 0.77 | PIK3C3 (0.43) | CHEK1AKT1AKT2PIK3CA | |
| SCHEMBL27273901 | 0.76 | DYRK1A (0.57) | DYRK1ACYP1A2METAP2TGFBR1KEAP1 | |
| SCHEMBL15743300 | 0.75 | DYRK1A (0.69) | DYRK1ACYP1A2METAP2TGFBR1KEAP1 | |
| SCHEMBL2537202 | 0.74 | SCN5A (0.52) | TGFBR1CHEK1AKT1AKT2NT5E | |
| SCHEMBL18584820 | 0.74 | DYRK1A (1.00) | DYRK1ACYP1A2TGFBR1KEAP1PIK3CA | |
| SCHEMBL1576521 | 0.74 | DYRK1A (0.73) | DYRK1ACYP1A2TGFBR1KEAP1CHEK1 | |
| SCHEMBL16554996 | 0.73 | DYRK1A (0.59) | DYRK1ATGFBR1CHEK1AKT1AKT2 | |
| SCHEMBL13861989 | 0.73 | MAP3K5 (0.48) | DYRK1ACHEK1AKT1AKT2NT5E | |
| SCHEMBL14320570 | 0.73 | DYRK1A (0.71) | DYRK1ACYP1A2TGFBR1KEAP1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730842-B2 | Small molecule inhibitors of DYRK1A and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730842-B2 | Small molecule inhibitors of DYRK1A and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3344039-A1 | SMALL MOLECULE INHIBITORS OF DYRK1A AND USES THEREOF | Arizona Board of Regents on behalf of the University of Arizona (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017040993-A1 | SMALL MOLECULE INHIBITORS OF DYRK1A AND USES THEREOF | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-03-09 | — | — | WO | disclosed |
| WO-2017040993-A1 | SMALL MOLECULE INHIBITORS OF DYRK1A AND USES THEREOF | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20110257171-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| EP-2318382-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS | Sanofi-Aventis (FR) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010007317-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730842-B2 | Small molecule inhibitors of DYRK1A and uses thereof | DYRK1A, DYRK2, DYRK1B | DYRK1A 1/4885CYP1A2 4476/4885METAP2 3800/4885 |
| US-20110257171-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS | MET, ALK, RET | DYRK1A 777/4885CYP1A2 183/4885METAP2 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.